Literature DB >> 18231114

Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels.

Tomoyuki Yoshihara1, Akihiko Taguchi, Tomohiro Matsuyama, Yoko Shimizu, Akie Kikuchi-Taura, Toshihiro Soma, David M Stern, Hiroo Yoshikawa, Yukiko Kasahara, Hiroshi Moriwaki, Kazuyuki Nagatsuka, Hiroaki Naritomi.   

Abstract

Increasing evidence points to a role for circulating endothelial progenitor cells, including populations of CD34-positive (CD34(+)) cells, in maintenance of cerebral blood flow. In this study, we investigated the link between the level of circulating CD34(+) cells and neovascularization at ischemic brain. Compared with control subjects, a remarkable increase of circulating CD34(+) cells was observed in patients with angiographic moyamoya vessels, although no significant change was observed in patients with major cerebral artery occlusion (or severe stenosis) but without moyamoya vessels. Our results suggest that the increased level of CD34(+) cells associated with ischemic stress is correlated with neovascularization at human ischemic brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18231114     DOI: 10.1038/jcbfm.2008.1

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  19 in total

1.  Recombinant human interleukin-11 treatment enhances collateral vessel growth after femoral artery ligation.

Authors:  Julius Aitsebaomo; Siddharth Srivastava; Hua Zhang; Sushmita Jha; Zhongjing Wang; Stephan Winnik; Anka N Veleva; Xinchun Pi; Pamela Lockyer; James E Faber; Cam Patterson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 2.  Collaterals: Implications in cerebral ischemic diseases and therapeutic interventions.

Authors:  Yasuo Nishijima; Yosuke Akamatsu; Phillip R Weinstein; Jialing Liu
Journal:  Brain Res       Date:  2015-03-11       Impact factor: 3.252

Review 3.  Progress in moyamoya disease.

Authors:  Shuling Shang; Da Zhou; Jingyuan Ya; Sijie Li; Qi Yang; Yuchuan Ding; Xunming Ji; Ran Meng
Journal:  Neurosurg Rev       Date:  2018-06-18       Impact factor: 3.042

Review 4.  Experimental Animal Models for Moyamoya Disease: A Species-Oriented Scoping Review.

Authors:  Lei Cao; Yang Dong; Kaiwen Sun; Dongpeng Li; Hao Wang; Hongwei Li; Bo Yang
Journal:  Front Surg       Date:  2022-07-01

Review 5.  Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy.

Authors:  Makoto Nabetani; Haruo Shintaku; Takashi Hamazaki
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

Review 6.  Pathological Circulating Factors in Moyamoya Disease.

Authors:  Yao-Ching Fang; Ling-Fei Wei; Chaur-Jong Hu; Yong-Kwang Tu
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

7.  Reduced ischemic brain injury by partial rejuvenation of bone marrow cells in aged rats.

Authors:  Akihiko Taguchi; Pengxiang Zhu; Fang Cao; Akie Kikuchi-Taura; Yukiko Kasahara; David M Stern; Toshihiro Soma; Tomohiro Matsuyama; Ryuji Hata
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-22       Impact factor: 6.200

Review 8.  Moyamoya Biomarkers.

Authors:  Edward R Smith
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

9.  Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients.

Authors:  Akihiko Taguchi; Chiaki Sakai; Toshihiro Soma; Yukiko Kasahara; David M Stern; Katsufumi Kajimoto; Masafumi Ihara; Takashi Daimon; Kenichi Yamahara; Kaori Doi; Nobuo Kohara; Hiroyuki Nishimura; Tomohiro Matsuyama; Hiroaki Naritomi; Nobuyuki Sakai; Kazuyuki Nagatsuka
Journal:  Stem Cells Dev       Date:  2015-08-17       Impact factor: 3.272

10.  Decreased levels of circulating CD34(+) cells are associated with coronary heart disease in Japanese patients with type 2 diabetes.

Authors:  Hisashi Makino; Yoshihiro Miyamoto; Akie Kikuchi-Taura; Toshihiro Soma; Akihiko Taguchi; Ichiro Kishimoto
Journal:  J Diabetes Investig       Date:  2014-12-13       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.